<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01486238</url>
  </required_header>
  <id_info>
    <org_study_id>PRESERVE</org_study_id>
    <nct_id>NCT01486238</nct_id>
  </id_info>
  <brief_title>Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study</brief_title>
  <acronym>PRESERVE</acronym>
  <official_title>Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valley Retina Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valley Retina Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intravitreal injections of pegaptanib every 4 weeks will be efficacious in treating Diabetic
      Macular Edema (DME), as compared to injections every 6 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 24 week clinical study which will be double-masked. Subjects will be randomly
      assigned 2:1 to Macugen® every 4 weeks (IVMac q4 arm) or Macugen® every 6 weeks (IVMac q6
      arm). If both eyes are eligible, then one eye will be randomized into the trial. Fellow eyes
      of patients with two eligible eyes will be monitored and treated with standard clinical care.
      If sufficient fellow eyes are treated, this will provide an internal control group for direct
      comparison of the Macugen® treated study eyes versus the fellow eyes. Both study eyes and
      fellow eyes will be assessed in the same fashion at every time point during this study.

      Each site is to have at least one Unmasked investigator to perform the study injections and
      one Masked investigator to perform study evaluations and assess adverse events. Roles cannot
      be reversed after study treatment for a given subject has begun.

      Patients assigned to IVMac q4 will receive a total of 6 intravitreal Macugen® injections
      administered at 4 week intervals beginning on Day 0 and ending at Week 20. Patients assigned
      to IVMac q6 will receive a total of 4 intravitreal Macugen® injections administered at 6 week
      intervals beginning on Day 0 and ending at Week 18. Each Macugen® injection will be
      administered as described in the package insert.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Subjects Who Gain Two or More Lines in Best Corrected Visual Acuity(BCVA) Score in the Study Eye Compared With Baseline.</measure>
    <time_frame>24 weeks</time_frame>
    <description>The primary efficacy outcome measure is the proportion of subjects who gain two or more lines in BCVA score in the Study Eye compared with baseline at 24 weeks. The BCVA is to be measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline at Week 24 in Central Foveal Thickness</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Optical Coherence Tomography (OCT) will be used to assess the central foveal thickness of each patient. The mean change from baseline to week 24 will be calculated for each patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects Requiring Macular Laser Treatment at Week 12 and Week 24.</measure>
    <time_frame>24 weeks</time_frame>
    <description>There is a possibility that some subjects may not respond to the study treatment to which they have been assigned. Macular laser treatment is considered an alternative treatment for retinal edema. A lower proportion of subjects requiring macular laser treatment would indicate a superior treatment regimen.
This will be assessed at week 12, and again at week 24.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>IVMac q6 Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients assigned to IVMac q6 will receive a total of 4 intravitreal Macugen® injections administered at 6week intervals beginning on Day 0 and ending at Week 18. Macugen® injection will be administered as described in the package insert.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IVMac q4 Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients assigned to IVMac q4 will receive a total of 6 intravitreal Macugen® injections administered at 4 week intervals beginning on Day 0 and ending at Week 20. Macugen® injection will be administered as described in the package insert.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Macugen® pegaptanib sodium</intervention_name>
    <description>Patients assigned to either arm (IVMac q4 and IVMac q6) will receive 0.3 milligrams (mg) of pegaptanib sodium delivered by intravitreal injection administered.
Patients assigned to IVMac q4 will receive a total of 6 intravitreal Macugen® injections administered at 4 week intervals beginning on Day 0 and ending at Week 20. Patients assigned to IVMac q6 will receive a total of 4 intravitreal Macugen® injections administered at 6 week intervals beginning on Day 0 and ending at Week 18. Each Macugen® injection will be administered as described in the package insert.</description>
    <arm_group_label>IVMac q6 Arm</arm_group_label>
    <arm_group_label>IVMac q4 Arm</arm_group_label>
    <other_name>Macugen® (pegaptanib sodium)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects must have macular edema that involves the center of the macula with
             corresponding leakage on fluorescein angiogram.

          2. Foveal thickness of at least 250 microns (OCT center point thickness), with a standard
             deviation of the center point of &lt;10%, an OCT signal strength of &gt; 5, and properly
             drawn ILM and RPE borders.

          3. Best corrected distance visual acuity in the study eye must 137 be a letter score
             between 70 and 20 inclusive (20/40 to 20/400 Snellen equivalents).

          4. Clear ocular media and adequate pupillary dilatation to permit good quality
             stereoscopic fundus photography.

          5. Intraocular pressure (IOP) of 21 mmHg or less (local anti-hypertensive medication of
             any duration permitted).

          6. The treating ophthalmologist should be comfortable that focal laser (direct and grid
             as needed) can be deferred for at least 18 weeks in the study eye, even though focal
             laser is indicated.

          7. Type I, or Type II diabetic subjects, of both genders, and aged 18 years.

          8. Women must be using effective contraception, be post-menopausal for at least 12 months
             prior to trial entry, or surgically sterile. All women of childbearing potential must
             have a negative serum pregnancy test at baseline and negative urine pregnancy tests
             immediately prior to each injection and use two effective forms of contraception
             during the trial and for at least 60 days following the last dose of pegaptanib
             sodium.

          9. Ability to provide written informed consent.

         10. Ability to return for all study visits.

        Exclusion Criteria:

          1. Eyes in which panretinal photocoagulation is needed now or is likely to be needed
             within the next 6 months.

          2. Eyes that have active PDR with high risk characteristics (HRC) as defined by the DRS:

               1. Mild neovascularization of the disc (NVD) of at least 1/3 disc area as shown in
                  standard photograph 10A of the DRS.

               2. Moderate neovascularization of the retina elsewhere (NVE) of at least 1/2 disc
                  area as shown in standard photograph 7 of the DRS.

          3. Presence of any abnormality that is likely to confound assessment of visual acuity
             improvement in eyes in which macular edema resolves, or improves, such as
             non-perfusion for &gt;1 disc area involving the foveal avascular zone, epiretinal
             membrane associated with signs of contraction and/or significant opacification, or
             presence of chorioretinal atrophy involving the center of the macula.

          4. Vitreomacular traction determined clinically and/or by OCT, which, in the
             investigator's opinion, contributes to the macular edema (or causes associated foveal
             detachment), and would preclude improvement with pegaptanib sodium

          5. Any other cause of macular edema such as vitreous extension, or entrapment to anterior
             segment wound, or any retinal vein occlusion involving the macula.

          6. Any subfoveal hard exudates, or RPE atrophy; or any present evidence, or past
             documentation of a foveal cyst (by fundus examination, FA or OCT).

          7. Previous treatment with intravitreal corticosteroids in the study eye within 3 months
             of Day 0 visit.

          8. Previous treatment with intravitreal anti-angiogenic drugs in the study eye within 3
             months of Day 0 visit.

          9. Previous PRP laser treatment in the study eye within 90 days of Day 0 visit.

         10. Subjects who have received YAG laser or peripheral retinal cryoablation or laser
             retinopexy (for retinal tears only), or focal photocoagulation within the previous 16
             weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Victor Gonzalez, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Valley Retina Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Valley Retina Institute,PA</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2011</study_first_submitted>
  <study_first_submitted_qc>December 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2011</study_first_posted>
  <results_first_submitted>April 2, 2013</results_first_submitted>
  <results_first_submitted_qc>June 12, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 16, 2013</results_first_posted>
  <last_update_submitted>June 12, 2013</last_update_submitted>
  <last_update_submitted_qc>June 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic Macular Edema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Papilledema</mesh_term>
    <mesh_term>Diabetic Angiopathies</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients will be recruited from a single medical clinic (Valley Retina Institute), and randomly assigned 2:1 to Macugen® every 4 weeks (IVMac q4 arm) or Macugen® every 6 weeks (IVMac q6 arm). If both eyes are eligible, then one eye will be randomized into the trial.</recruitment_details>
      <pre_assignment_details>All enrolled patients must have DME in one or both eyes. In patients with both eyes that meet criteria, only 1 eye will be considered eligible. All fellow eyes in these patients will be treated according to standard clinical guidelines.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>IVMac q6 Arm</title>
          <description>Patients assigned to IVMac q6 will receive a total of 4 intravitreal Macugen® injections administered at 6week intervals beginning on Day 0 and ending at Week 18. Macugen® injection will be administered as described in the package insert.</description>
        </group>
        <group group_id="P2">
          <title>IVMac q4 Arm</title>
          <description>Patients assigned to IVMac q4 will receive a total of 6 intravitreal Macugen® injections administered at 4 week intervals beginning on Day 0 and ending at Week 20. Macugen® injection will be administered as described in the package insert.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>In the IVMac q6 Arm, 23 subjects started the study. Two (2) subjects withdrew early. For this reason data from the 21 remaining subjects was used.
In the IVMac q4 Arm, 49 subjects started the study. 6 subjects were lost in this arm - 2 died, 1 withdrew, &amp; 3 were lost to follow-up. For this reason data from the 43 remaining subjects was used.</population>
      <group_list>
        <group group_id="B1">
          <title>IVMac q6 Arm</title>
          <description>Patients assigned to IVMac q6 will receive a total of 4 intravitreal Macugen® injections administered at 6week intervals beginning on Day 0 and ending at Week 18. Macugen® injection will be administered as described in the package insert.</description>
        </group>
        <group group_id="B2">
          <title>IVMac q4 Arm</title>
          <description>Patients assigned to IVMac q4 will receive a total of 6 intravitreal Macugen® injections administered at 4 week intervals beginning on Day 0 and ending at Week 20. Macugen® injection will be administered as described in the package insert.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="43"/>
            <count group_id="B3" value="64"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" spread="10"/>
                    <measurement group_id="B2" value="62" spread="30"/>
                    <measurement group_id="B3" value="62.5" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Subjects Who Gain Two or More Lines in Best Corrected Visual Acuity(BCVA) Score in the Study Eye Compared With Baseline.</title>
        <description>The primary efficacy outcome measure is the proportion of subjects who gain two or more lines in BCVA score in the Study Eye compared with baseline at 24 weeks. The BCVA is to be measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol.</description>
        <time_frame>24 weeks</time_frame>
        <population>Proportion of subjects who gain two or more lines BCVA was calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>IVMac q6 Arm</title>
            <description>Patients assigned to IVMac q6 will receive a total of 4 intravitreal Macugen® injections administered at 6week intervals beginning on Day 0 and ending at Week 18. Macugen® injection will be administered as described in the package insert.</description>
          </group>
          <group group_id="O2">
            <title>IVMac q4 Arm</title>
            <description>Patients assigned to IVMac q4 will receive a total of 6 intravitreal Macugen® injections administered at 4 week intervals beginning on Day 0 and ending at Week 20. Macugen® injection will be administered as described in the package insert.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Who Gain Two or More Lines in Best Corrected Visual Acuity(BCVA) Score in the Study Eye Compared With Baseline.</title>
          <description>The primary efficacy outcome measure is the proportion of subjects who gain two or more lines in BCVA score in the Study Eye compared with baseline at 24 weeks. The BCVA is to be measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol.</description>
          <population>Proportion of subjects who gain two or more lines BCVA was calculated.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline at Week 24 in Central Foveal Thickness</title>
        <description>Optical Coherence Tomography (OCT) will be used to assess the central foveal thickness of each patient. The mean change from baseline to week 24 will be calculated for each patient.</description>
        <time_frame>24 Weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects Requiring Macular Laser Treatment at Week 12 and Week 24.</title>
        <description>There is a possibility that some subjects may not respond to the study treatment to which they have been assigned. Macular laser treatment is considered an alternative treatment for retinal edema. A lower proportion of subjects requiring macular laser treatment would indicate a superior treatment regimen.
This will be assessed at week 12, and again at week 24.</description>
        <time_frame>24 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>IVMac q6 Arm</title>
          <description>Patients assigned to IVMac q6 will receive a total of 4 intravitreal Macugen® injections administered at 6week intervals beginning on Day 0 and ending at Week 18. Macugen® injection will be administered as described in the package insert.</description>
        </group>
        <group group_id="E2">
          <title>IVMac q4 Arm</title>
          <description>Patients assigned to IVMac q4 will receive a total of 6 intravitreal Macugen® injections administered at 4 week intervals beginning on Day 0 and ending at Week 20. Macugen® injection will be administered as described in the package insert.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Septicemia</sub_title>
                <description>not related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Congestive Heart Failure</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Uncontrolled High Blood Pressure</sub_title>
                <description>not related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic Ketoacidosis</sub_title>
                <description>not related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Neovascularization of the Iris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Ischemic Neuropathy left eye</sub_title>
                <description>not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Non study drug related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Severe Retrosternal Chest Pain</sub_title>
                <description>not related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Unknown Death</sub_title>
                <description>cause of death was unknown upon completion of the trial</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Unknown Death</sub_title>
                <description>cause of death was unknown at the completion of the trial</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Left Hip Fracture</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>not related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <description>not related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>not related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Left Foot Abcess</sub_title>
                <description>not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Victor Gonzalez, MD</name_or_title>
      <organization>Valley Retina Institute, PA</organization>
      <phone>956-631-8875</phone>
      <email>research@vritx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

